INA01 and new generations of antibodies are targeting the transferrin receptor (CD71).
CD71 regulates cellular activation and proliferation. Preclinical studies have shown that tumor cells, with high proliferative capacity, strongly express the CD71 receptor. Therefore antibody against CD71 will preferentially target cancer cells.
INA02 is an anti-CD89 antibody. The CD89 is expressed on the surface of many cells involved in inflammation. Indeed INA02 takes effect prior to the inflammatory process in the body. INA02 binds itself onto CD89 receptor expressed only by inflammatory cells and reduces the release of the mediators responsible for the inflammation.
Inatherys, a biotechnology company from academic research.
Founded in 2009, Inatherys is a biotechnology company spin-off from INSERM (Institut National de la Santé et de la Recherche Médicale).
The founders come from academic research units.
in partnership with Adult Hematology Department of Necker Hospital, Paris
Inatherys' strength lies in the meeting of a team of research, onco/hematology physicians, entrepreneurs and pharmaceutical development specialists.
Our medical, scientific and monoclonal antibodies development expertise, perfected for more than 20 years, is recognized on the international stage.
Cancers and severe inflammatory diseases: a public health issue
Every year, 12 million people are affected by cancers in the world. Severe inflammatory diseases handicap hundreds of millions of people.
Inatherys' mission is to design and develop innovative molecules providing solutions for the treatment of
Inatherys' monoclonal antibodies INA01 and INA02 meet a real medical need.
These molecules have demonstrated their effectiveness in preclinical phase and will be developed in patients in advanced stages of their disease, when traditional treatments are no longer effective.